Wave's Duchenne program comes to a screeching halt — now all eyes will be on Huntington's
Wave Life Sciences is folding its hand in Duchene muscular dystrophy after an interim analysis of a Phase I open-label extension trial revealed its lead drug simply does not work.
In addition to discontinuing two trials involving suvodirsen, including a Phase II/III confirmatory trial for the exon 51 skipping therapy, the biotech is also suspending further development of a different molecule designed for patients with mutations amenable to exon 53 skipping.
The implosion triggered a 50% plunge on the stock $WVE, which is trading now at $18.85 — reflecting how, ahead of the bad news, “more than half of the investors’ valuation was DMD” according to Stifel analyst Paul Matteis.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.